Home   >  
Protease/Metabolic Enzyme
  • Protease/Metabolic Enzyme
  >  
IDH

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

IDH

Chemical Structure Cat. No. Product Name CAS No.
Olutasidenib Chemical Structure
BCP30919 Olutasidenib 1887014-12-1
Olutasidenib is a potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 for the treatment of acute myeloid leukemia.
IDH-305 Chemical Structure
BCP30411 IDH-305 1628805-46-8
IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH).
GSK321 Chemical Structure
BCP20143 GSK321 1816331-63-1
GSK321 is a potent and selective IDH1 mutant inhibitor.
BAY-1436032 Chemical Structure
BCP18989 BAY-1436032 1803274-65-8
BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
Mutant IDH1-IN-1 Chemical Structure
BCP13615 Mutant IDH1-IN-1 1355326-21-4
Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent); more bioactivity information in Patent WO2012009678A1.
Mutant IDH1 inhibitor Chemical Structure
BCP16459 Mutant IDH1 inhibitor 1429180-08-4
Mutant IDH1 Inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
Mutant IDH1-IN-2 Chemical Structure
BCP16464 Mutant IDH1-IN-2 1429176-69-1
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
AGI6780 Chemical Structure
BCP07383 AGI6780 1432660-47-3
AGI-6780 is the first highly potent and selective small molecule inhibitor of isocitrate dehydrogenases, which binds in an allosteric manner at the dimer interface of mutant IDH2-R140Q.
AGI-5198 Chemical Structure
BCP07382 AGI-5198 1355326-35-0
AGI-5198, a novel R132H-IDH1 inhibitor, identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG).
Ivosidenib Chemical Structure
BCP15362 Ivosidenib 1448347-49-6
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells.
12下一页共 15 条记录 1 / 2 页 
0086-15971444841